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Objective: To test the hypothesis that high circulating concen-
trations of maternal anti-angiogenic factors are associated 
with increased risk of respiratory distress syndrome (RDS). 
Study Design: This is a nested case-control study of nulliparous 
women who delivered less than 37 weeks of gestation within 
the Calcium for Preeclampsia Prevention (CPEP) trial. The study 
included 116 women with preeclampsia or gestational hyperten-
sion and 323 normotensive controls. Soluble fms-like tyrosine 
kinase 1 (sFlt1), placental growth factor (PlGF) and soluble endo-
glin (sEng) in maternal serum were measured at 21–32 weeks of 
gestation. Results: Preterm infants born to hypertensive mothers 
were more likely to develop RDS (22.5% vs. 20.9%, p = 0.03). 
After adjustment for gestational age at delivery, the odds ratio 
for the relationship between hypertension in pregnancy and 
RDS was 2.18 (95% CI 1.08–4.39). In hypertensive pregnancies 
women whose infants developed RDS had significantly higher 
circulating mean sFlt1 levels during midpregnancy (21–32 
weeks of gestation) even after adjustment for gestational age at 
delivery (21,516 pg/mL vs. 7,000 pg/mL, p = 0.01). Conclusions: 
Preterm preeclampsia and gestational hypertension, charac-
terized by high circulating levels of sFlt1, are associated with 
a twofold increased risk of RDS in infants delivered before 37 
weeks. Among women with these hypertensive pregnancies 
circulating sFlt1 concentrations during midpregnancy were 
substantially higher in women whose infants developed RDS.
Keywords:  Anti-angiogenic, soluble fms-like tyrosine kinase 1, 
sVEGF R1, sFlt1, placental growth factor, PlGF, soluble endoglin, 
sEng, respiratory distress syndrome, RDS, neonate, preterm, 
preeclampsia, gestational hypertension
Introduction
Preeclampsia is a progressive disease characterized clinically by 
new onset hypertension and proteinuria which typically develops 
during the last half of pregnancy. Also with onset in pregnancy 
≥20 weeks of gestation, gestational hypertension refers to hyper-
tension without proteinuria. Especially when it occurs remote 
from  term,  gestational  hypertension  frequently  progresses  to 
preeclampsia [1]. Preeclampsia and gestational hypertension are 
important causes of preterm delivery [2,3].
One of the most common and severe complications of preterm 
delivery is respiratory distress syndrome (RDS). Reports on the 
relationship  between  preeclampsia  or  gestational  hypertension 
and the occurrence of neonatal RDS have been divided, given 
the difficulty in accounting for confounding variables such as 
mode of delivery [4–9] and birth weight [4–9]. Neonatal respi-
ratory distress syndrome is caused by insufficient production of 
surfactant by immature alveolar type 2 pneumocytes. Clinical 
evidence of RDS appears immediately or within a few hours after 
birth. It is characterized by tachypnea, retractions, nasal flaring, 
grunting and cyanosis. Lung maturation is a complicated and 
incompletely  understood  process.  Vascular  endothelial  growth 
factor (VEGF), which binds to the receptors Flk-1 (also known as 
VEGF receptor-2) and Flt-1 (also known as VEGF receptor-1) is 
important for pulmonary vascular development [10]. Moreover, 
VEGF has been shown to increase surfactant protein production 
[11], and treatment with VEGF prevents fatal respiratory distress 
in premature mice [12]. Lower VEGF concentrations in tracheal 
aspirate fluid have been found in preterm infants of women with 
preeclampsia [13].
Preeclampsia and gestational hypertension are both character-
ized by an altered angiogenic state with high levels of anti-angio-
genic  factors,  especially  when  these  conditions  occur  preterm 
[14–17]. Blood concentrations of sFlt1, a soluble VEGF receptor 
produced during pregnancy that binds VEGF and placental growth 
factor (PlGF), increase during the last 2 months of normal preg-
nancy and attain much greater levels in women with preeclampsia 
or gestational hypertension [16,18,19]. Studies in both humans 
and animals suggest that an imbalance in circulating pro- and 
anti-angiogenic factors resulting in excess blood concentrations 
of anti-angiogenic factors such as soluble fms-like tyrosine kinase 
(sFlt1 or sVEGFR1) is responsible for the clinical manifestations 
of the disease [20–22]. Soluble endoglin, another anti-angiogenic 
protein, which acts by inhibiting TGF-β signaling, has also been 
shown to play a pathogenic role in preeclampsia [16,22].
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We hypothesized that the high circulating concentrations of 
anti-angiogenic  factors  in  hypertensive  pregnancies  would  be 
associated with an increased risk for RDS. We performed a nested 
case-control study of women who delivered less than 37 weeks of 
gestation within the Calcium for Preeclampsia Prevention (CPEP) 
trial. We compared the risk of RDS in infants from normotensive 
and hypertensive pregnancies and serum angiogenic factor levels 
among women whose infants did or did not develop RDS.
Methods
Participants and specimens
The  CPEP  trial  was  a  randomized,  double-blind  clinical  trial 
conducted during 1992-1995 in healthy nulliparous women with 
singleton pregnancies to evaluate the effects of daily supplemen-
tation with calcium on the incidence and severity of preeclampsia 
[23]. Calcium supplementation had no effect on the incidence, 
severity, or gestational age at onset of preeclampsia or on the inci-
dence of gestational hypertension.
Enrollment occurred between 13 and 21 weeks of gestation 
at five medical centers in the United States. Nulliparous women 
were  followed  from  enrollment  until  24  hours  after  delivery. 
Women were excluded from study entry if they had a history of 
hypertension or renal disease, elevated serum creatinine (≥1 mg/
dL), or elevated blood pressure (≥135/85 mm Hg) or proteinuria 
(≥1+ [30 mg/dL] by dipstick) at either of two screening visits prior 
to study enrollment at 13–21 weeks of gestation. Serum samples 
were requested before enrollment, at 26–29 weeks of gestation, 
36 weeks of gestation, and when preeclampsia was suspected. 
Specimens were stored at −70°C.
Among  all  4589  women  in  CPEP,  300  were  excluded  for 
the  following  reasons:  253  lost  to  follow-up,  21  whose  preg-
nancy  terminated  before  20  weeks,  17  missing  maternal  or 
perinatal  outcome  data,  and  9  with  unverified  hypertension. 
Of the remaining 4289, 451 (10.5%) delivered before 37 weeks. 
Twelve women with gestational proteinuria were excluded. Of 
the remaining 439 women, 116 with gestational hypertension or 
preeclampsia were considered the cases, and 323 normotensive 
women served as controls.
Hypertension  was  defined  as  a  diastolic  blood  pressure 
≥90 mm on two occasions occurring 4 to 168 hours (1 week) 
apart.  Gestational  hypertension  was  the  onset  of  hyperten-
sion after 20 weeks of gestation. Proteinuria was defined by (a) 
24-hour urine collection of ≥300 mg protein, (b) a single random 
urine specimen with a protein/creatinine ratio ≥0.35, (c) ≥2+ 
(100 mg/dL) protein by dipstick in one random specimen or (d) 
1+ (30 mg/dL) protein in two random urine specimens occur-
ring 4 to 168 hours apart. Preeclampsia was the occurrence of 
gestational hypertension and gestational proteinuria within 7 
days of each other. Respiratory distress syndrome (RDS) was 
defined  as  the  acute  onset  of  respiratory  distress  (grunting, 
retractions,  increased  oxygen  requirement  [FiO2 > 0.4], 
tachypnea [>60 breaths per minute]) with diagnostic radio-
graphic findings in the absence of evidence for other causes of 
respiratory distress. Neonatal data were collected prospectively 
as part of the CPEP trial. Gestational age was determined by 
the earliest obstetrical ultrasound prior to study enrollment. 
A  small-for-gestational-age  infant  had  a  birth  weight  below 
the 10th percentile according to U.S. tables of birth weight for 
gestational age that accounted for race, parity and sex of the 
infant.[24]
Because specimens could not be linked to identifiable records, 
the Office of Human Subjects Research of the National Institutes 
of  Health  granted  the  study  an  exemption  from  the  require-
ment for review and approval by the institutional review board. 
Written consent was given by all CPEP study participants prior 
to enrollment.
Procedures
Enzyme-linked immunosorbent assays for human sFlt1, soluble 
endoglin (sEng) and PlGF had previously been conducted in dupli-
cate by R&D Systems Analytical Testing Services (Minneapolis, 
MN,  USA)  in  all  serum  specimens  obtained  from  a  random 
sample of 2200 women within the CPEP trial cohort and all other 
women  who  developed  preeclampsia.[21]  Of  the  439  preterm 
mother–infant pairs, 165/323 (51%) normotensive pregnancies 
and 85/116 (73%) hypertensive pregnancies (66/70 or 94% with 
preeclampsia and 19/46 or 41% with gestational hypertension) 
had serum angiogenic factor concentrations measured at least 
once during pregnancy.
Statistical analysis
The χ2 test was used to compare categorical variables. The t test 
was  used  to  compare  continuous  variables.  For  comparison 
of  maternal  characteristics,  the  entire  population  was  used. 
Comparison  of  serum  angiogenic  factor  levels  was  limited  to 
the 57% with samples. Angiogenic factor levels were compared 
at study enrollment (10–20 weeks) and at midpregnancy (21–32 
weeks). When a woman had more than one serum sample within 
an interval, the sample obtained latest was used. Statistical compar-
isons of specimens from cases and controls were conducted using 
linear  models,  adjusting  for  gestational  age  when  appropriate. 
Multivariate logistic regression was used to estimate the odds 
ratio (OR) of RDS after controlling for gestational age at delivery. 
Logistic  models  were  developed  for  RDS.  These  included  the 
independent variables log sFlt1, gestational age at delivery, birth 
weight and cesarean section.
Results
Characteristics of the women and infants
At the time of enrollment women with preeclampsia or gesta-
tional  hypertension  had  higher  systolic  and  diastolic  blood 
pressure, weight and body mass index (BMI) than normoten-
sive  women  (Table  I).  No  statistically  significant  differences 
were noted between hypertensive and normotensive groups in 
terms of race/ethnicity, parity, maternal age, calcium treatment 
and gestational age at enrollment. Twice as many normoten-
sive women smoked, but this difference was not statistically 
significant.
Perinatal  outcomes  are  presented  in  Table  II.  RDS  was 
diagnosed in 87 infants. A significantly greater proportion of 
preterm infants born to hypertensive mothers had RDS than 
preterm  infants  born  to  normotensive  mothers  (22.5%  vs. 
20.9%, p = 0.03, after adjustment for gestational age at delivery). 
The likelihood of developing RDS was greater in infants born 
of hypertensive pregnancies than of pregnancies complicated 
by other causes of preterm delivery. After adjustment for gesta-
tional age, the odds ratio for the relationship between preec-
lampsia/gestational hypertension and RDS was 2.18 (95% C.I. 
1.08–4.39). As the risk of RDS is mediated in part by other 
potential confounders, we further examined logistic models. 
Consistent with previously published studies [8,9], gestational 
age at delivery and delivery by cesarean section, but not birth 
weight, were also significantly associated with increased risk 
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Hypertensive mothers on average delivered a week later than 
their normotensive counterparts (34.3 vs. 33.2 weeks, p = 0.002) 
and were more likely to have had a cesarean delivery (32.8% vs. 
13%, p < 0.001). Infants delivered to hypertensive and normoten-
sive mothers had similar birth weights, but infants of hypertensive 
mothers were more likely to be small for gestational age (SGA). 
Although the finding was not statistically significant, there was 
also a slight increase in neonatal mortality in those infants who 
delivered to normotensive mothers (4.4%) compared with hyper-
tensive mothers (1.8%).
Angiogenic and anti-angiogenic factor levels
We then compared angiogenic and anti-angiogenic factor levels 
in normotensive (Table III) and hypertensive pregnancies (Table 
IV) at baseline (10–20 weeks) and midpregnancy (21–32 weeks) 
between  women  who  had  infants  with  and  without  RDS.  As 
expected, regardless of whether pregnancy was normotensive or 
hypertensive, infants with RDS were born at significantly earlier 
gestational ages than infants without RDS. Women who remained 
normotensive  during  pregnancy  delivered  fewer  infants  who 
developed RDS. When comparing serum pro- and anti-angiogenic 
factor levels at 10–20 and at 21–32 weeks in normotensive women 
whose infants did or did not develop RDS, no significant differ-
ences were observed (Table III).
In  hypertensive  pregnancies,  women  whose  infants  would 
develop RDS had substantially higher sFlt1 levels at midpreg-
nancy (Table IV). A scatter plot that contrasts circulating sFlt1 
in hypertensive women who delivered infants with and without 
RDS  is  displayed  in  Figure  1.  Eight  of  17  (47%)  sFlt1  values 
exceeded 20,000 pg/ml at midpregnancy in women with infants 
who developed RDS, whereas only 1 of 53 (2%) sFlt1 values did 
so in women whose infants did not develop RDS. This difference 
in  sFlt1  concentrations  during  midpregnancy  (21–32  weeks) 
remained  significant  after  adjustment  for  gestational  age  at 
delivery (mean 21,516 pg/mL vs. 7000 pg/mL, p = 0.01). Logistic 
modeling indicated that of midpregnancy log sFlt1, gestational 
age at delivery, birth weight, and cesarean section, only log sFlt1 
(pg/ml) (coefficient 1.01, p = 0.02) and gestational age at delivery 
(days) (coefficient−0.06, p = 0.002) were significantly associated 
with the risk of RDS. Controlling for birth weight and cesarean 
section did not change the association.
Soluble  endoglin  was  elevated,  and  PlGF  was  decreased  at 
midpregnancy  in  hypertensive  mothers  who  delivered  infants 
with  RDS,  although  significance  was  lost  after  adjustment  for 
gestational age. Serum concentrations of pro- and anti-angiogenic 
proteins, after adjustment, were also not significantly different 
at 10–20 weeks in hypertensive women whose infants would or 
would not develop RDS (Table IV).
Discussion
Hypertensive disorders of pregnancy have deleterious effects on 
both the mother and the fetus. It has been shown in animals and 
Table I.  Maternal characteristics at study enrollment for women with 





(n = 116) p value
Age (years) 20.8 ± 4.8* 20.3 ± 3.8 NS
Weight (kg) 65.7 ± 15.4 69.9 ± 19.5 0.04
BMI 25.1 ± 5.5 27 ± 7.7 0.02
SBP (mm Hg) 105.8 ± 8.4 109.2 ± 8.9 <0.001
DBP (mm Hg) 58.9 ± 7.8 63.2 ± 8.1 <0.001
GA at enrollment (days) 122.4 ± 17.6 120.7 ± 17.8 NS
Current smoker 39 (12.1%) 7 (6.0%) NS
Previous pregnancy 100 (31.0%) 26 (22.4%) NS
Race/ethnicity
  White, non-Hispanic 83 (25.7%) 26 (22.4%)  
  White, Hispanic 50 (15.5%) 15 (12.9%) NS
  Black 184 (57.0%) 70 (60.3%)  
  Other, unknown 6 (1.9%) 5 (4.3%)  
Calcium treatment 166 (51.4%) 62 (53.5%) NS
*Data are presented as mean ± SD or N (%). Hypertensive = preeclampsia or gestational 
hypertension; Calcium treatment = assigned to receive supplemental calcium; BMI, 
body-mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; GA, 
gestational age; NS, not significant.
Table II.  Perinatal outcomes for women with delivery <37 weeks in 





(n = 116) p value
GA at delivery (weeks) 33.2 ± 4.3* 34.3 ± 3.0 0.002±
Cesarean section 42 (13.0%) 38 (32.8%) <0.001±
Neonatal death 13 (4.4%) 2 (1.8%) NS
Birth weight (g) 2080 ± 788 2038 ± 640 NS
SGA 18 (6.1%) 32 (28.3%) <0.001±
Male 178 (55.1%) 60 (52.2%) NS
Respiratory distress 
syndrome
62 (20.9%) 25 (22.5%) NS±/0.03†
Intraventricular hemorrhage 21 (7.1%) 5 (4.5%) NS±/NS†
Necrotizing enterocolitis 5 (1.7%) 1 (0.9%) NS±/NS†
*Data are presented as mean ± SD or N (%). Hypertensive = preeclampsia or gestational 
hypertension; GA, gestational age; SGA, small for gestational age; NS, not significant. 
±Indicates significance without adjustment. †Indicates significance with adjustment 
for gestational age at delivery.
Table III.  Comparison of serum concentrations of sFlt1, PlGF, and sEng 
among normotensive women who delivered preterm infants with or 
without respiratory distress syndrome, in specimens collected at 10–20 or 
21–32 weeks.
  RDS No RDS p value
Collected at 10–20 weeks
  Number of women 25 111  
  GA at collection (weeks) 17.0 ± 0.5* 16.2 ± 0.2 NS±
  GA at delivery (weeks) 29.4 ± 0.8 34.7 ± 0.3 <0.001±
  Cesarean section 6 (24.0%) 10 (9.0%) NS±/NS†
  Birth weight (g) 1404 ± 137 2315 ± 55 <0.001±/NS†
  SGA 0 (0.0%) 8 (7.2%) NS±/NS†
  sFlt1 (pg/mL) 3895 ± 494 3542 ± 177 NS±/NS†
  PlGF (pg/mL) 207 ± 32 146 ± 12 0.05±/NS†
  sEng (ng/mL) 6.30 ± 1.0 5.45 ± 0.1 NS±/NS†
Collected at 21–32 weeks
  Number of women 14 117  
  GA at collection (weeks) 26.5 ± 0.5 27.1 ± 0.1 NS±
  GA at delivery (weeks) 32.1 ± 0.9 35.2 ± 0.2 0.005±
  Cesarean section 3 (21.4%) 11 (9.4%) NS±/NS†
  Birth weight (g) 1865 ± 169 2410 ± 42 <0.001±/NS†
  SGA 0 (0.0%) 8 (6.8%) NS±/NS†
  sFlt1 (pg/mL) 3645 ± 504 4430 ± 222 NS±/NS†
  PlGF (pg/mL) 491 ± 63 706 ± 59 NS±/NS†
  sEng (ng/mL) 5.32 ± 0.3 5.67 ± 0.2 NS±/NS†
*Data are presented as mean ± SD or N (%). RDS, respiratory distress syndrome; GA, 
gestational age; SGA, small for gestational age; sFlt1, soluble fms-like tyrosine kinase 
1;  PlGF,  placental  growth  factor;  sEng,  soluble  endoglin.  ±Indicates  significance 
without adjustment.  †Indicates significance with adjustment for gestational age at 
delivery.1450  A. Wang et al.
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in humans that an excess of circulating anti-angiogenic factors 
such as sFlt1 and soluble endoglin may play a pathogenic role in 
the development of maternal proteinuria and elevated blood pres-
sure, the characteristic clinical signs of preeclampsia [17,20–22]. 
The relationship between preeclampsia and RDS, however, has 
been a subject of controversy [4–9,25]. In the present study, we 
report a twofold increased risk of RDS in preterm infants born 
to nulliparous women with preeclampsia or gestational hyperten-
sion, after adjustment for gestational age at delivery.
As  preeclampsia  [18]  and  lung  immaturity  [24]  are  both 
characterized by a relative VEGF-deficient state, we tested the 
hypothesis  that  angiogenic  and  anti-angiogenic  modulatory 
factors are further dysregulated in women whose pregnancies are 
complicated by hypertensive disease and whose infants develop 
RDS. We found that a higher mean serum sFlt1 level in hyper-
tensive pregnancies is associated with increased risk for RDS. 
Using logistic models, we also showed that a higher serum sFlt1 
concentration  in  hypertensive  pregnancies  is  associated  with 
increased risk for RDS even after taking into account gestational 
age at delivery, birth weight, and cesarean delivery. The latter two 
potential confounders were found to be unrelated to RDS risk 
when log sFlt1 and gestational age at delivery were included in 
the model.
Our study confirms the results of investigations by Jelin [8] 
and Tubman [9] which report that RDS is more common in 
infants of hypertensive mothers. In our study with relatively 
small sample size, we detected a modest difference in the risk 
of RDS in preterm infants exposed to maternal preeclampsia or 
gestational hypertension. Similar to Jelin et al., we also noted 
that there was no longer a statistically significant increased risk 
for RDS after controlling for mode of delivery in our study (data 
not shown), suggesting that the increased risk of RDS may be 
partially related to the higher frequency of cesarean delivery in 
women with hypertensive disease. However, when log sFlt1 and 
gestational age at delivery were included in our logistic model, 
we found that cesarean delivery as a potential confounder to be 
unrelated to RDS risk, suggesting a potential correlation between 
sFlt1  and  cesarean  delivery.  This  would  reflect  the  difficulty 
in  disentangling  mode  of  delivery  from  severity  of  maternal 
hypertensive disease as many diseased pregnancies necessitate 
an iatrogenic operative delivery. In addition to mode of delivery, 
there  may  be  multiple  other  confounding  factors  that  could 
affect our results, notably differences in clinical management, 
such as the delivery of antenatal steroids, mechanical ventilation 
and surfactant use.
Information  about  maternal  antenatal  steroid  use  was  not 
available  but  assumed  to  be  equal  among  both  normotensive 
and  hypertensive  women  as  samples  were  collected  within  a 
limited 3-year period (1992–1995). Before 1995, it was reported 
that only 20% of premature infants in the United States were 
treated, with substantial local variations in practice [26]. With 
the  evolution  of  surfactant  and  antenatal  glucocorticoids,  we 
recognize that there may be effects of improved outcome and 
that the lack of information about lung maturity induction in 
this cohort represents a significant weakness for our study. We 
also noted slightly increased neonatal mortality in the preterm 
control infants (4.4%) compared with infants who delivered to 
hypertensive mothers (1.8%); however, this finding did not reach 
statistical significance, given the sample size. The slight increase 
in mortality in the preterm control group may be due to many 
of the same confounding factors as discussed above as well as a 
lower gestational age.
Hypertensive mothers on average delivered a week later than 
their normotensive counterparts (34.3 vs. 33.2 weeks). The higher 
mean gestational age at delivery ≥34 weeks and the increase in RDS 
risk may reflect a possible clinical practice that antenatal steroids 
may not have been given to hypertensive women because the 
pregnancies were greater than 34 ± 0 weeks of gestation. However, 
our findings would suggest that antenatal steroids are especially 
critical in pregnancies complicated by gestational hypertension or 
preeclampsia given the increased RDS risk in these pregnancies. 
We would argue that the traditional benchmark of 34 weeks of 
gestation as the cutoff for antenatal steroid delivery be examined 
and perhaps altered for hypertensive pregnancies.
Table IV.  Comparison of serum concentrations of sFlt1, PlGF and sEng 
among hypertensive women who delivered preterm infants with or without 
respiratory distress syndrome, in specimens collected at 10–20 or 21–32 
weeks.
  RDS No RDS p value
Collected at 10–20 weeks
  Number of women 18 55  
  GA at collection (weeks) 15.9 ± 0.6* 16.1 ± 0.4 NS±
  GA at delivery (weeks) 31.2 ± 0.8 35.4 ± 0.2 <0.001±
  Cesarean section 12 (66.7%) 11 (20%) <0.001±/NS†
  Birth weight (g) 1410 ± 155 2207 ± 64 <0.001±/NS†
  SGA 8 (44.4%) 17 (30.9%) NS±/NS†
  sFlt1 (pg/mL) 4841 ± 1081 3216 ± 214 0.03±/NS†
  PlGF (pg/mL) 108 ± 33 115 ± 14 NS±/NS†
  sEng (ng/mL) 8.31 ± 1.9 6.61 ± 0.4 NS±/NS†
Collected at 21–32 weeks
  Number of women 17 53  
  GA at collection (weeks) 27.9 ± 0.5 27.6 ± 0.2 NS
  GA at delivery (weeks) 31.6 ± 0.8 35.2 ± 0.2 <0.001±
  Cesarean section 11 (64.7%) 11 (20.8%) <0.001±/NS†
  Birth weight (g) 1420 ± 156 2201 ± 75 <0.001±/NS†
  SGA 9 (52.9%) 15 (28.3%) NS±/0.045†
  sFlt1 (pg/mL) 21516 ± 3734 6998 ± 674 <0.001±/0.01†
  PlGF (pg/mL) 215 ± 136 344 ± 56 0.002±/NS†
  sEng (ng/mL) 30.63 ± 5.7 16.07 ± 2.6 0.003±/NS†
*Data are presented as mean ± SD or N (%). Hypertensive = preeclampsia or gestational 
hypertension; RDS, respiratory distress syndrome; GA, gestational age; SGA, small 
for gestational age; sFlt1, soluble fms-like tyrosine kinase 1; PlGF, placental growth 
factor; sEng, soluble endoglin. ±Indicates significance without adjustment. †Indicates 
significance with adjustment for gestational age at delivery.
Figure  1.  Maternal  serum  concentrations  of  sFlt1  (pg/ml)  in  specimens 
collected at 21–32 weeks of gestation in women with preeclampsia/gestational 
hypertension by gestational age at collection (days) and according to whether 
neonates did or did not develop respiratory distress syndrome (RDS).Anti-angiogenic factors and  respiratory distress syndrome  1451
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Our study is also limited by the lack of detailed information 
regarding the postnatal courses of the preterm infants, especially 
the severity of RDS and the development of bronchopulmonary 
dysplasia. A recent study by Hansen et al. has shown an asso-
ciation between bronchopulmonary dysplasia and preeclampsia 
[27]. Also, our study encompasses a broad gestational age range, 
including all infants delivered at less than 37 weeks. As preterm 
gestational hypertension has poor pregnancy outcomes [28] and 
high circulating concentrations of anti-angiogenic proteins [16], 
we have grouped together gestational hypertension and preec-
lampsia to obtain adequate power in this study. In studies with 
larger sample size, there may be not only a higher prevalence of 
RDS but also a greater disease severity that may be seen in infants 
with maternal preeclampsia compared with maternal gestational 
hypertension.  As  our  study  was  cross-sectional  in  nature,  we 
cannot exclude the possibility that the rate of rise of sFlt1 during 
midpregnancy may have had a stronger relationship with subse-
quent RDS.
The association between hypertensive diseases of pregnancy 
and RDS is biologically plausible, as both are characterized by rela-
tive VEGF deficiency. After comparison of multiple angiogenic 
factors including soluble endoglin and PlGF, we find a significant 
association of RDS only with sFlt1. A truncated splice variant of 
the membrane-bound VEGF receptor Flt1, sFlt1 antagonizes both 
VEGF and PlGF by binding them in the circulation, preventing 
interaction with their endogenous receptors [29], and affecting 
their downstream signaling. Free VEGF and PlGF concentrations 
in maternal serum are reduced in preeclampsia [20]. Maternal 
circulating sFlt1 concentration has been shown to correlate with 
maternal disease severity and to be greater when preeclampsia or 
gestational hypertension occur preterm [14,17]. There are also 
increases  in  anti-angiogenic  factor  concentrations  in  the  fetal 
circulation of pregnancies with preeclampsia; however, compared 
with maternal sera, cord blood levels of sFlt1 are very low [30]. 
However, previous studies have reported very high concentrations 
of sFlt1 in third trimester amniotic fluid just prior to delivery. The 
median sFlt1 concentration in the amniotic fluid of preeclamptic 
pregnancies (51,040 pg/ml at 33 weeks) was 1.5-fold elevated as 
compared with the median amniotic fluid sFlt1 concentration of 
the control group (33,490 pg/ml at 39 weeks) [30]. As circulating 
sFlt1 in normotensive women rises with increasing gestation, a 
greater difference in amniotic fluid sFlt1 would be expected if 
preeclamptic and control specimens had been obtained at similar 
gestational ages. A recent study also reported elevated sFlt1 in the 
amniotic fluid of women several months prior to clinical signs of 
preeclampsia [31]. As the amniotic fluid bathes the developing 
lung and is an important source of surfactant [32], it is tempting 
to speculate that the high sFlt1 concentrations in the amniotic 
fluid of women with preterm gestational hypertension or preec-
lampsia may inhibit VEGF signaling, leading to surfactant defi-
ciency. Although sFlt1 is secreted into the maternal circulation 
primarily by the syncytiotrophoblasts [33], the sources of sFlt1 in 
the fetal circulation and in the amniotic fluid are not known.
In summary, this study supports a modestly increased risk 
of  RDS  in  neonates  delivered  from  pregnancies  with  preterm 
preeclampsia or gestational hypertension. It indicates that RDS 
in neonates born to these hypertensive pregnancies is correlated 
with high levels of the anti-angiogenic factor sFlt1 in maternal 
blood and suggests that inhibition of VEGF by high levels of sFlt1 
in amniotic fluid may reduce surfactant. Observational studies 
in women and experimental studies in animals are needed to 
examine the relationship between amniotic fluid levels of sFlt1 
and the subsequent development of RDS.
Acknowledgments
This study was supported by the intramural research program 
of the Eunice Kennedy Shriver National Institute of Child Health 
and  Human  Development,  National  Institutes  of  Health,  US 
Department of Health and Human Services to R.J.L; and by the 
Howard Hughes Medical Institute to S.A.K. Dr. Wang receives 
funding from the Flight Attendant Medical Research Institute.
Declaration of Interest: Dr. Karumanchi reports having served 
as  a  consultant  to  Beckman  Coulter  and  Roche  and  having 
been named co-inventor on multiple patents filed by Beth Israel 
Deaconess  Medical  Center  for  the  use  of  angiogenesis-related 
proteins  for  the  diagnosis  and  treatment  of  preeclampsia.  Dr. 
Karumanchi has financial interest in Aggamin LLC. Dr. Toporsian 
is a co-inventor on a patent related to use of soluble endoglin in 
preeclampsia. All other authors have nothing to declare.
References
  1.  Barton  JR,  O’brien  JM,  Bergauer  NK,  Jacques  DL,  Sibai  BM.  Mild 
gestational hypertension remote from term: progression and outcome. 
Am J Obstet Gynecol 2001;184:979–983.
  2.  Ananth CV, Joseph KS, Oyelese Y, Demissie K, Vintzileos AM. Trends in 
preterm birth and perinatal mortality among singletons: United States, 
1989 through 2000. Obstet Gynecol 2005;105:1084–1091.
  3.  Sibai BM. Diagnosis and management of gestational hypertension and 
preeclampsia. Obstet Gynecol 2003;102:181–192.
  4.  Bowen JR, Leslie GI, Arnold JD, Jones MP, Gallery ED. Increased incidence of 
respiratory distress syndrome in infants following pregnancies complicated 
by hypertension. Aust N Z J Obstet Gynaecol 1988;28:109–112.
  5.  Brazy  JE,  Grimm  JK,  Little  VA.  Neonatal  manifestations  of  severe 
maternal  hypertension  occurring  before  the  thirty-sixth  week  of 
pregnancy. J Pediatr 1982;100:265–271.
  6.  Chiswick ML. Prolonged rupture of membranes, pre-eclamptic toxaemia, 
and respiratory distress syndrome. Arch Dis Child 1976;51:674–679.
  7.  Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm 
delivery  for  preeclampsia.  Am  J  Obstet  Gynecol  1995;172:1785–8; 
discussion 1788.
  8.  Jelin AC, Cheng YW, Shaffer BL, Kaimal AJ, Little SE, Caughey AB. 
Early-onset  preeclampsia  and  neonatal  outcomes.  J  Matern  Fetal 
Neonatal Med 2010;23:389–392.
  9.  Tubman TR, Rollins MD, Patterson C, Halliday HL. Increased incidence 
of  respiratory  distress  syndrome  in  babies  of  hypertensive  mothers. 
Arch Dis Child 1991;66:52–54.
10.  Ferrara  N.  Role  of  vascular  endothelial  growth  factor  in  regulation 
of  physiological  angiogenesis.  Am  J  Physiol,  Cell  Physiol 
2001;280:C1358–C1366.
11.  Chen  CM,  Wang  LF.  High-dose  vascular  endothelial  growth  factor 
increases surfactant protein gene expressions in preterm rat lung. Early 
Hum Dev 2007;83:581–584.
12.  Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, 
Plaisance S, et al. Loss of HIF-2alpha and inhibition of VEGF impair 
fetal  lung  maturation,  whereas  treatment  with  VEGF  prevents  fatal 
respiratory distress in premature mice. Nat Med 2002;8:702–710.
13.  Lassus P, Ristimäki A, Ylikorkala O, Viinikka L, Andersson S. Vascular 
endothelial growth factor in human preterm lung. Am J Respir Crit 
Care Med 1999;159:1429–1433.
14.  Chaiworapongsa  T,  Romero  R,  Espinoza  J,  Bujold  E,  Mee  Kim  Y, 
Gonçalves  LF,  Gomez  R,  Edwin  S.  Evidence  supporting  a  role  for 
blockade  of  the  vascular  endothelial  growth  factor  system  in  the 
pathophysiology  of  preeclampsia.  Young  Investigator  Award.  Am  J 
Obstet Gynecol 2004;190:1541–7; discussion 1547.
15.  Hirashima C, Ohkuchi A, Takahashi K, Suzuki H, Yoshida M, Ohmaru 
T, Eguchi K, et al. Gestational hypertension as a subclinical preeclampsia 
in view of serum levels of angiogenesis-related factors. Hypertens Res 
2011;34:212–217.
16.  Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, et al.; 
CPEP Study Group. Soluble endoglin and other circulating antiangiogenic 
factors in preeclampsia. N Engl J Med 2006;355:992–1005.
17.  Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman 
EF, et al. Circulating angiogenic factors and the risk of preeclampsia. N 
Engl J Med 2004;350:672–683.1452  A. Wang et al.
   The Journal of Maternal-Fetal and Neonatal Medicine
18.  Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza 
J, Bujold E, et al. Plasma soluble vascular endothelial growth factor 
receptor-1 concentration is elevated prior to the clinical diagnosis of 
pre-eclampsia. J Matern Fetal Neonatal Med 2005;17:3–18.
19.  Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. 
Prospective study of placental angiogenic factors and maternal vascular 
function before and after preeclampsia and gestational hypertension. 
Circulation 2010;122:478–487.
20.  Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann 
TA, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may 
contribute to endothelial dysfunction, hypertension, and proteinuria in 
preeclampsia. J Clin Invest 2003;111:649–658.
21.  Holston  AM,  Qian  C,  Yu  KF,  Epstein  FH,  Karumanchi  SA,  Levine 
RJ. Circulating angiogenic factors in gestational proteinuria without 
hypertension. Am J Obstet Gynecol 2009;200:392.e1–392.10.
22.  Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, 
Bdolah Y, et al. Soluble endoglin contributes to the pathogenesis of 
preeclampsia. Nat Med 2006;12:642–649.
23.  Levine RJ, Hauth JC, Curet LB, Sibai BM, Catalano PM, Morris CD, 
DerSimonian R, et al. Trial of calcium to prevent preeclampsia. N Engl 
J Med 1997;337:69–76.
24.  Zhang  J,  Bowes  WA  Jr.  Birth-weight-for-gestational-age  patterns  by 
race, sex, and parity in the United States population. Obstet Gynecol 
1995;86:200–208.
25.  Yoon  JJ,  Kohl  S,  Harper  RG.  The  relationship  between  maternal 
hypertensive  disease  of  pregnancy  and  the  incidence  of  idiopathic 
respiratory distress syndrome. Pediatrics 1980;65:735–739.
26.  Fanaroff AA, Wright LL, Stevenson DK, Shankaran S, Donovan EF, 
Ehrenkranz RA, Younes N, et al. Very-low-birth-weight outcomes of the 
National Institute of Child Health and Human Development Neonatal 
Research Network, May 1991 through December 1992. Am J Obstet 
Gynecol 1995;173:1423–1431.
27.  Hansen AR, Barnés CM, Folkman J, McElrath TF. Maternal preeclampsia 
predicts  the  development  of  bronchopulmonary  dysplasia.  J  Pediatr 
2010;156:532–536.
28.  Hauth JC, Ewell MG, Levine RJ, Esterlitz JR, Sibai B, Curet LB, Catalano 
PM,  Morris  CD.  Pregnancy  outcomes  in  healthy  nulliparas  who 
developed hypertension. Calcium for Preeclampsia Prevention Study 
Group. Obstet Gynecol 2000;95:24–28.
29.  Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth 
factor activity by an endogenously encoded soluble receptor. Proc Natl 
Acad Sci USA 1993;90:10705–10709.
30.  Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating 
concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and 
maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod 
Biol 2005;122:33–39.
31.  Wang CN, Chang SD, Peng HH, Lee YS, Chang YL, Cheng PJ, Chao 
AS, et al. Change in amniotic fluid levels of multiple anti-angiogenic 
proteins before development of preeclampsia and intrauterine growth 
restriction. J Clin Endocrinol Metab 2010;95:1431–1441.
32.  Lee DC, Romero R, Kim CJ, Chaiworapongsa T, Tarca AL, Lee J, Suh 
YL,  et  al.  Surfactant  protein-A  as  an  anti-inflammatory  component 
in  the  amnion:  implications  for  human  pregnancy.  J  Immunol 
2010;184:6479–6491.
33.  Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia 
R, Charnock-Jones DS. A vascular endothelial growth factor antagonist 
is  produced  by  the  human  placenta  and  released  into  the  maternal 
circulation. Biol Reprod 1998;59:1540–1548.